ZNF217 promoted oncogenic phenotypes in all ovarian cancer cells we tested so far, demonstrating that ZNF217 functions as an oncogene independent of the p53 mutation status of cancer cells and can promote tumor progression and therapeutic resistance in a broad spectrum of ovarian cancer patients who differ in their tumor p53 status. This evidence concerns the gene ZNF217 and ovarian carcinoma.